Aoxing Pharmaceutical Company, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended December 31, 2012
February 15, 2013 at 11:06 am
Share
Aoxing Pharmaceutical Company, Inc. announced earnings results for the second quarter and six months ended December 31, 2012. For the quarter, the company reported revenue of $3,314,768, representing a 56% increase over the revenues realized in the same period last year. Loss from operations was $2,352,385 compared with $150,860 a year ago. Net loss was $3,135,661. The increase in revenue was mainly attributable to the increase in sales of main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market.
For the six months, the company reported revenue of $5,919,531, representing a 62% increase over the revenues realized in the same period last year. Loss from operations was $2,264,906 compared with $646,817 a year ago. Net loss was $3,584,176.
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The Company holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter (OTC) and active pharmaceutical ingredient (API) products. Its products include prescription drugs, such as Tilidine hydrochloride, Zhongtong'an and Humifuse Euphorbia Herb Tablet, and OTC drugs, such as Shanmei Capsule, Shaoshang Tincture, Yiqi Qiangshen Granule, Xiaopiling Granule, Xiongjushangqing Tablet, Juyuansuanbijia Oral Solutions, Longdanxiegan Tablet, Fenka Tablet, Shujinhuoxue Tablet, Fuketiaojing Tablet, Qingnao Jiangya Tablet, Yuanhu Pain Management Tablet, Bushenqiangshen Tablet, Baiziyangxin Pill, Qingguo Pill, Liuweidihuang Pill, Zhibaidihuang Pill, Xiaoyao Pill and Tianwangbuxin Pill.